Mining Tissue Microarray Data to Uncover Combinations of Biomarker Expression Patterns that Improve Intermediate Staging and Grading of Clear Cell Renal Cell Cancer

Purpose: Tumor stage and nuclear grade are the most important prognostic parameters of clear cell renal cell carcinoma (ccRCC). The progression risk of ccRCC remains difficult to predict particularly for tumors with organ-confined stage and intermediate differentiation grade. Elucidating molecular pathways deregulated in ccRCC may point to novel prognostic parameters that facilitate planning of therapeutic approaches. Experimental Design: Using tissue microarrays, expression patterns of 15 different proteins were evaluated in over 800 ccRCC patients to analyze pathways reported to be physiologically controlled by the tumor suppressors von Hippel-Lindau protein and phosphatase and tensin homologue (PTEN). Tumor staging and grading were improved by performing variable selection using Cox regression and a recursive bootstrap elimination scheme. Results: Patients with pT2 and pT3 tumors that were p27 and CAIX positive had a better outcome than those with all remaining marker combinations. A prolonged survival among patients with intermediate grade (grade 2) correlated with both nuclear p27 and cytoplasmic PTEN expression, as well as with inactive, nonphosphorylated ribosomal protein S6. By applying graphical log-linear modeling for over 700 ccRCC for which the molecular parameters were available, only a weak conditional dependence existed between the expression of p27, PTEN, CAIX, and p-S6, suggesting that the dysregulation of several independent pathways are crucial for tumor progression. Conclusions: The use of recursive bootstrap elimination, as well as graphical log-linear modeling for comprehensive tissue microarray (TMA) data analysis allows the unraveling of complex molecular contexts and may improve predictive evaluations for patients with advanced renal cancer. Clin Cancer Res; 16(1); 88–98

[1]  B. Delahunt,et al.  Reassessing the current UICC/AJCC TNM staging for renal cell carcinoma. , 2009, European urology.

[2]  H. Moch,et al.  Loss of VHL and Hypoxia Provokes PAX2 Up-Regulation in Clear Cell Renal Cell Carcinoma , 2009, Clinical Cancer Research.

[3]  H. Moch,et al.  Diagnostic and prognostic molecular markers for renal cell carcinoma: a critical appraisal of the current state of research and clinical applicability. , 2009, European urology.

[4]  N. Probst-Hensch,et al.  Prognostic Significance of Epithelial-Mesenchymal and Mesenchymal-Epithelial Transition Protein Expression in Non–Small Cell Lung Cancer , 2008, Clinical Cancer Research.

[5]  W. Krek,et al.  pVHL: A Multipurpose Adaptor Protein , 2008, Science Signaling.

[6]  A. Vortmeyer,et al.  Combined Vhlh and Pten Mutation Causes Genital Tract Cystadenoma and Squamous Metaplasia , 2008, Molecular and Cellular Biology.

[7]  B. Jasani,et al.  Combined expression of caveolin-1 and an activated AKT/mTOR pathway predicts reduced disease-free survival in clinically confined renal cell carcinoma , 2008, British Journal of Cancer.

[8]  S. Manna,et al.  Suppression of renal cell carcinoma growth by inhibition of Notch signaling in vitro and in vivo. , 2008, The Journal of clinical investigation.

[9]  J. Cheville,et al.  Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  C. Magi-Galluzzi,et al.  The prognostic significance of epidermal growth factor receptor expression in clear-cell renal cell carcinoma: a call for standardized methods for immunohistochemical evaluation. , 2007, Clinical genitourinary cancer.

[11]  E. Cho,et al.  p53 stabilization and transactivation by a von Hippel-Lindau protein. , 2006, Molecular cell.

[12]  Patrick H. Maxwell,et al.  Contrasting Properties of Hypoxia-Inducible Factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-Associated Renal Cell Carcinoma , 2005, Molecular and Cellular Biology.

[13]  S. Signoretti,et al.  Carbonic Anhydrase IX Expression Predicts Outcome of Interleukin 2 Therapy for Renal Cancer , 2005, Clinical Cancer Research.

[14]  I. Sesterhenn,et al.  World health organization classifications of tumours. pathology and genetics of tumours of the urinary system and male genital organs , 2005 .

[15]  C. Supuran,et al.  Hypoxia activates the capacity of tumor‐associated carbonic anhydrase IX to acidify extracellular pH , 2004, FEBS letters.

[16]  V. Ficarra,et al.  Neoplasm staging and organ-confined renal cell carcinoma: a systematic review. , 2004, European urology.

[17]  P. Rehak,et al.  Biological significance of p27 and Skp2 expression in renal cell carcinoma. A systematic analysis of primary and metastatic tumour tissues using a tissue microarray technique , 2004, Virchows Archiv.

[18]  Ying Yan,et al.  Ectopic expression of von Hippel-Lindau tumor suppressor induces apoptosis in 786-O renal cell carcinoma cells and regresses tumor growth of 786-O cells in nude mouse. , 2004, Biochemical and biophysical research communications.

[19]  William R Sellers,et al.  The biology and clinical relevance of the PTEN tumor suppressor pathway. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  P. Rehak,et al.  Are heterogenous results of EGFR immunoreactivity in renal cell carcinoma related to non-standardised criteria for staining evaluation? , 2004, Journal of Clinical Pathology.

[21]  Ryan M. Anderson,et al.  Acquired Expression of Periostin by Human Breast Cancers Promotes Tumor Angiogenesis through Up-Regulation of Vascular Endothelial Growth Factor Receptor 2 Expression , 2004, Molecular and Cellular Biology.

[22]  Min Cheol Lee,et al.  Expression of PTEN in renal cell carcinoma and its relation to tumor behavior and growth , 2003, Journal of surgical oncology.

[23]  G. Landberg,et al.  Expression of cyclin D1, D3, E, and p27 in human renal cell carcinoma analysed by tissue microarray , 2003, British Journal of Cancer.

[24]  Steve Horvath,et al.  Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[25]  J. Cheville,et al.  Comparison of standardized and nonstandardized nuclear grade of renal cell carcinoma to predict outcome among 2,042 patients. , 2002, American journal of clinical pathology.

[26]  Carlos L. Arteaga,et al.  PKB/Akt mediates cell-cycle progression by phosphorylation of p27Kip1 at threonine 157 and modulation of its cellular localization , 2002, Nature Medicine.

[27]  Y. Oda,et al.  Low expression of p27Kip1 is associated with tumor size and poor prognosis in patients with renal cell carcinoma , 2002 .

[28]  D. Figarella-Branger,et al.  Pax-2 expression in adult renal tumors. , 2001, Human pathology.

[29]  P. Pandolfi,et al.  Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse , 2001, Nature Genetics.

[30]  H. Moch,et al.  Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell carcinoma , 2000, Cancer.

[31]  P. Chu,et al.  Paraffin-section detection of CD10 in 505 nonhematopoietic neoplasms. Frequent expression in renal cell carcinoma and endometrial stromal sarcoma. , 2000, American journal of clinical pathology.

[32]  Michele Pagano,et al.  SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27 , 1999, Nature Cell Biology.

[33]  A. Schäffer,et al.  Evaluation of the clonal relationship between primary and metastatic renal cell carcinoma by comparative genomic hybridization. , 1999, The American journal of pathology.

[34]  J. Dixon,et al.  PTEN: a tumour suppressor that functions as a phospholipid phosphatase. , 1999, Trends in cell biology.

[35]  H. Brauch,et al.  Prevalence, morphology and biology of renal cell carcinoma in von Hippel-Lindau disease compared to sporadic renal cell carcinoma. , 1998, The Journal of urology.

[36]  J. Kononen,et al.  Tissue microarrays for high-throughput molecular profiling of tumor specimens , 1998, Nature Medicine.

[37]  J. Herman,et al.  Point mutation and homozygous deletion of PTEN/MMAC1 in primary bladder cancers , 1998, Oncogene.

[38]  R. Klausner,et al.  The von Hippel-Lindau tumor suppressor gene is required for cell cycle exit upon serum withdrawal. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[39]  J. Herman,et al.  Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. , 1997, Cancer research.

[40]  B. Delahunt,et al.  The Heidelberg classification of renal cell tumours , 1997, The Journal of pathology.

[41]  J. Srigley,et al.  Current prognostic factors‐renal cell carcinoma , 1997 .

[42]  T. Pisansky,et al.  Current prognostic factors--renal cell carcinoma: Workgroup No. 4. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). , 1997, Cancer.

[43]  P. Bugert,et al.  Mutation of the p53 tumour suppressor gene occurs preferentially in the chromophobe type of renal cell tumour , 1997, The Journal of pathology.

[44]  G. Dressler,et al.  The PAX2 tanscription factor is expressed in cystic and hyperproliferative dysplastic epithelia in human kidney malformations. , 1996, The Journal of clinical investigation.

[45]  P. Gruss,et al.  Loss of p53 function through PAX‐mediated transcriptional repression. , 1995, The EMBO journal.

[46]  J. Gnarra,et al.  Expression of Pax-2 in human renal cell carcinoma and growth inhibition by antisense oligonucleotides. , 1995, Cancer research.

[47]  M. Kenward,et al.  An Introduction to the Bootstrap , 2007 .

[48]  Massimo Loda,et al.  Role of p27 in Prostate Carcinogenesis , 2004, Cancer and Metastasis Reviews.

[49]  Y. Oda,et al.  Low expression of p27(Kip1) is associated with tumor size and poor prognosis in patients with renal cell carcinoma. , 2002, Cancer.

[50]  Cdm Fletcher,et al.  World Health Organization Classification of Tumours , 2002 .